Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04373460 · ClinicalTrials.gov registry record · Phase 2
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
A Phase 2 study of SARS-CoV-2, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,225
- Enrollment target
- 20
- Study locations
NCT04373460 is a Phase 2 study of SARS-CoV-2 that has completed, run by Johns Hopkins University. The registered enrollment target is 1,225 participants, below the 3,726-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04373460, a Phase 2 study of SARS-CoV-2, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,225 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
Conditions Studied
Interventions
- BIOLOGICAL SARS-CoV-2 convalescent plasma
- BIOLOGICAL Plasma from a volunteer donor
Study Locations (20)
Arizona
- Center for American Indian Health - Chinle Office - Chinle
- Mayo Clinic, Phoenix - Phoenix
- University of Arizona, Phoenix - Tucson
- University of Arizona, Tuscon - Tucson
- Center for American Indian Health - Whiteriver Office - Whiteriver
Maryland
- Anne Arundel Medical Center - Annapolis
- The Johns Hopkins University - Baltimore
- MedStar Washington Hospital Center - Hyattsville
California
- University of California, Los Angeles - Los Angeles
- University of California, Irvine Health - Orange
Connecticut
- Western Connecticut Health Network, Danbury Hospital - Danbury
- Western Connecticut Health Network, Norwalk Hospital - Norwalk
Florida
- University of Miami - Coral Gables
- University of Miami Clinical Translational Research Site - Miami
Alabama
- University of Alabama at Birmingham - Birmingham
Illinois
- NorthShore University HealthSystem - Evanston
Louisiana
- Tulane University - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,225 participants |
| Start Date | 2020-06-03 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04373460
The ClinicalTrials.gov registry entry for NCT04373460 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,225 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,726-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (67% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 2 interventions - of which SARS-CoV-2 convalescent plasma is the first listed.
NCT04373460 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Arizona, Maryland, California.
Frequently Asked Questions
What is clinical trial NCT04373460 about?
NCT04373460 is a clinical study titled "Convalescent Plasma to Limit SARS-CoV-2 Associated Complications". To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
What is the current status of trial NCT04373460?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,225 participants. The study started on 2020-06-03. Estimated completion is 2022-12-14.
What conditions does trial NCT04373460 study?
This clinical trial studies the following conditions: SARS-CoV-2.
What interventions are being tested in trial NCT04373460?
The interventions under investigation include: SARS-CoV-2 convalescent plasma (BIOLOGICAL), Plasma from a volunteer donor (BIOLOGICAL).
Who is sponsoring clinical trial NCT04373460?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04373460 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
COMPLETED · Phase 2
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
RECRUITING · Phase 4
-
Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads
RECRUITING · NA
-
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
RECRUITING
-
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.